List of Excipients in Branded Drug HABITROL NICOTINE POLACRILEX 4 MG COATED CINNAMON

Generic Drugs Containing HABITROL NICOTINE POLACRILEX 4 MG COATED CINNAMON

Company	Ingredient	NDC	Excipient
Dr Reddy's Laboratories Inc	nicotine polacrilex	55741-001	ACACIA
Dr Reddy's Laboratories Inc	nicotine polacrilex	55741-001	ACESULFAME POTASSIUM
Dr Reddy's Laboratories Inc	nicotine polacrilex	55741-001	BUTYLATED HYDROXYTOLUENE

What are the Most Frequently-Used Excipients in HABITROL NICOTINE POLACRILEX 4 MG COATED CINNAMON?

# Of NDCs	Excipient
1	ACACIA
1	ACESULFAME POTASSIUM
1	BUTYLATED HYDROXYTOLUENE

Last updated: August 30, 2026

ecutive summary: Habitrol Nicotine Polacrilex 4 mg Coated Cinnamon is an over-the-counter nicotine replacement therapy delivered as medicated chewing gum. Its commercial value depends less on molecule-level exclusivity and more on excipient control, nicotine release, taste masking, chew texture, manufacturing scale, and retailer access. Nicotine polacrilex has no meaningful remaining composition-of-matter patent barrier. The strongest opportunities are private-label supply, flavor and coating upgrades, pediatric-resistant packaging, lower-cost regional manufacturing, and differentiated nicotine gum formats.

Habitrol Nicotine Polacrilex 4 mg Coated Cinnamon: Excipient Strategy and Commercial Opportunities

What is Habitrol nicotine polacrilex 4 mg coated cinnamon?

Habitrol 4 mg coated cinnamon is a nicotine replacement therapy gum containing 4 mg of nicotine polacrilex per piece. Nicotine polacrilex is a nicotine-resin complex that releases nicotine during chewing and buffering in the oral cavity.

The product is intended for adults who smoke 25 or more cigarettes per day or require the higher starting strength under a standard nicotine-cessation schedule. FDA-recognized nicotine gum products use 2 mg and 4 mg strengths, with gradual dose reduction during treatment.[1]

Attribute	Product profile
Brand	Habitrol
Active ingredient	Nicotine polacrilex
Strength	4 mg nicotine per piece
Dosage form	Medicated chewing gum
Flavor	Cinnamon
Route	Buccal and oral mucosal absorption
Regulatory category	OTC nicotine replacement therapy
Primary use	Smoking cessation
Closest branded competitor	Nicorette nicotine gum
Main commercial channel	Pharmacies, mass retail, e-commerce, smoking-cessation programs

The “coated” designation indicates an external coating or finish around the medicated gum core. That coating can influence taste onset, cinnamon intensity, moisture protection, product appearance, and handling during packaging.

What excipients are strategically important in nicotine polacrilex gum?

The principal excipient platform consists of gum base, sweeteners, buffers, humectants, lubricants or processing aids, and flavoring agents. Exact excipient composition can vary by manufacturer, market, and production site. The commercial objective is to release nicotine gradually while maintaining acceptable chewability and flavor.

Core excipient functions

Excipient class	Typical function	Commercial relevance
Gum base	Provides chewable matrix and controls mechanical release	Determines chew profile, manufacturing throughput, and consumer acceptance
Sorbitol or other polyol	Bulk sweetener and texture modifier	Supports sugar-free positioning and affects cooling sensation
Sodium carbonate or bicarbonate	Raises local pH and improves nicotine liberation	Directly affects nicotine delivery and onset
Glycerol or other humectant	Controls moisture and flexibility	Reduces brittleness and improves shelf stability
Cinnamon flavor	Provides taste and masks nicotine bitterness	Differentiates the product but creates irritation and stability risks
Coating materials	Protect the gum, control first taste, and improve appearance	Can create proprietary release and sensory performance
Talc, waxes, or processing aids	Reduce sticking and support manufacturing	Relevant to compression, wrapping, and high-speed packaging
High-intensity sweeteners	Improve palatability at low mass loading	Can reduce sugar content and modify aftertaste

For a 4 mg product, the buffer system is particularly important. Nicotine is a weak base, and absorption across the buccal mucosa improves when the formulation creates a more favorable local pH. Excessive alkalinity can produce throat irritation, harshness, and poor repeat use. The commercial target is controlled nicotine release without a sharp alkaline taste.

How does the cinnamon coating affect formulation performance?

The cinnamon coating is a potential source of differentiation, but it also introduces formulation risk.

A coating can provide four commercial functions:

1. It can delay direct contact between the user and the nicotine-containing core.
2. It can deliver cinnamon flavor before the nicotine taste becomes prominent.
3. It can reduce moisture transfer during storage.
4. It can improve visual uniformity and consumer recognition.

Cinnamon flavor systems may contain volatile aldehydes, including cinnamaldehyde, that can interact with packaging, migrate, or produce oral irritation at higher exposure levels. Flavor intensity must be balanced against nicotine harshness and repeated daily use. A strong initial flavor may improve trial but reduce persistence if users experience burning, throat irritation, or excessive aftertaste.

A commercially robust coating should have:

• Low friability during transport
• Stable adhesion to the gum core
• Controlled dissolution in saliva
• Limited tackiness under elevated humidity
• Compatibility with foil or blister packaging
• Consistent cinnamon release across production lots
• No material impact on nicotine assay or degradation products

The coating is more likely to support trade-secret protection than a durable patent position. Manufacturing parameters, coating weight, spray conditions, drying profile, flavor particle size, and packaging humidity controls can create meaningful replication barriers.

What formulation patents protect nicotine gum products?

The original patent landscape for nicotine gum covered nicotine-resin complexes, chewing-gum delivery systems, buffering, and controlled nicotine release. Those early rights generally have expired or reached the end of their enforceable terms.

IP category	Current commercial importance
Nicotine polacrilex composition patents	Low; foundational rights are generally expired
Basic nicotine gum patents	Low; established technology is broadly available
Buffering and pH-control claims	Moderate only where narrow, later-filed claims remain active
Flavor and coating claims	Potentially moderate, depending on claim scope and filing date
Manufacturing-process patents	Moderate if they cover specific coating, drying, or release methods
Packaging patents	Moderate for child-resistant, moisture-control, or unit-dose formats
Trade secrets	High for process settings, gum-base handling, and sensory optimization

A freedom-to-operate analysis should focus on later patents covering specific coated-gum structures, multiparticulate nicotine systems, controlled-release matrices, and manufacturing methods. The existence of broad expired nicotine-gum patents does not eliminate risk from narrow process or packaging claims.

What is the Orange Book status of Habitrol nicotine gum?

Habitrol nicotine gum is generally regulated as an OTC smoking-cessation product rather than as a conventional prescription NDA product. FDA’s OTC monograph framework for smoking-cessation products establishes conditions for active ingredients, strengths, labeling, and dosage forms.[1]

As a result:

• An Orange Book patent listing is not the primary exclusivity mechanism.
• A conventional Paragraph IV strategy is generally not the central pathway for competing products.
• FDA monograph compliance and product-specific quality requirements are more important than Orange Book patent certification.
• A product marketed under an approved NDA, if applicable to a specific presentation, would require separate verification from the monograph pathway.

The commercial implication is significant. Competitors can enter without waiting for a long brand patent term if they comply with the applicable OTC requirements, secure lawful marketing status, and demonstrate product quality.

When does Habitrol nicotine gum lose exclusivity?

Habitrol’s practical market exclusivity has already expired at the technology level. Nicotine polacrilex gum is an established OTC dosage form with multiple competing products and private-label versions.

Exclusivity category	Assessment
Active ingredient exclusivity	Expired or unavailable for commercial protection
Basic dosage-form exclusivity	Expired
New chemical entity exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	No product-specific barrier is expected to control the category
Brand exclusivity	Limited to trademark and consumer recognition
Formulation exclusivity	Possible only through narrow active patents or trade secrets
Retail exclusivity	Negotiated, not statutory

Brand value can persist after patent expiry through flavor recognition, retailer placement, consumer trust, and repeat-purchase behavior. Cinnamon provides a potential brand anchor, but it does not create meaningful regulatory exclusivity.

What generic entry risks exist for Habitrol 4 mg cinnamon gum?

Generic and private-label entry risk is high. The product uses an established active ingredient and a familiar OTC dosage form. Competitors can target the same 4 mg strength with conventional gum bases, standard buffering systems, and equivalent labeling.

The main entry barriers are operational rather than legal:

• Consistent nicotine content per piece
• Uniform nicotine release
• Acceptable chew texture
• Control of cinnamon flavor variability
• Low migration of volatile flavor components
• Stable performance under high humidity
• Reliable wrapping and blister packaging
• FDA-compliant labeling and manufacturing controls

A low-cost entrant may match the active ingredient but fail on taste, gum hardness, coating adhesion, or nicotine release. Those failures can limit repeat purchases even when the product is technically substitutable.

Which companies compete with Habitrol nicotine gum?

Nicotine gum competition includes branded products, store brands, contract manufacturers, and nicotine-pouch companies.

Competitor group	Competitive advantage
Nicorette and related branded products	Brand recognition, clinical familiarity, broad flavor portfolio
Pharmacy and mass-retail private labels	Lower price and strong shelf access
Contract manufacturers	Flexible production and customer-specific packaging
Nicotine lozenge suppliers	Easier administration for users who do not want to chew
Nicotine-pouch companies	Discreet use, modern branding, and expanding flavor ranges
Digital cessation programs	Bundled adherence support and recurring product sales

Nicotine gum remains relevant for users who want rapid, user-controlled dosing. Nicotine lozenges and pouches compete through convenience and discreet use, while patches compete through continuous delivery.

How does Habitrol 4 mg gum compare with nicotine lozenges and patches?

Attribute	4 mg nicotine gum	Nicotine lozenge	Nicotine patch
Dosing control	High; user controls chewing	Moderate; dissolution controls delivery	Low after application
Onset	Relatively rapid	Relatively rapid	Slow and sustained
Behavioral substitution	High because chewing replaces oral habit	Moderate	Low
Taste risk	High	High	Minimal
Adherence risk	Chewing technique and jaw discomfort	Mouth irritation and taste	Skin irritation
Formulation complexity	High gum-base and release complexity	Moderate solid-dose complexity	Adhesive and transdermal complexity
Manufacturing barrier	Moderate to high	Moderate	High
Private-label opportunity	High	High	Moderate

The strongest commercial positioning for cinnamon gum is behavioral substitution plus rapid, self-controlled dosing. The principal weakness is user technique. Patients must chew slowly and park the gum to avoid swallowing nicotine-containing saliva, nausea, hiccups, and throat irritation.[2]

What formulation improvements create commercial opportunities?

1. Improved taste and irritation control

A redesigned cinnamon system could use layered flavor release, lower initial cinnamaldehyde intensity, or a cooling secondary note. The objective is to reduce nicotine bitterness without producing excessive heat or oral burning.

2. Enhanced moisture protection

Unit-dose blistering, high-barrier foil, and improved coating integrity can extend shelf stability. This is particularly relevant for distribution in tropical or high-humidity regions.

3. Texture optimization

A softer initial chew can improve patient acceptance, while controlled resilience can prolong nicotine release. Gum-base selection and plasticizer concentration are central variables.

4. Lower-sugar and clean-label positioning

Sugar-free formulations using polyols can support diabetic-friendly and dental-health positioning, subject to labeling and tolerability controls. Excess polyol content can increase gastrointestinal complaints, so the sweetener system requires careful optimization.

5. Smaller and more discreet pieces

A thinner or smaller gum unit could improve portability and reduce social stigma. The formulation must preserve the 4 mg nicotine load without producing excessive chewing hardness or dose variability.

6. Combination cessation kits

Commercial bundles can combine 4 mg gum with nicotine patches, behavioral support, adherence reminders, or pharmacist counseling. The opportunity lies in packaging and service integration rather than new chemical exclusivity.

What manufacturing and IP barriers affect commercial entry?

The major manufacturing barriers are process consistency and quality control. Nicotine polacrilex must be distributed uniformly through the gum matrix. Inadequate mixing can create content uniformity failures, while excessive heat can alter flavor and nicotine stability.

Critical process parameters include:

• Gum-base softening temperature
• Mixing time and shear
• Nicotine-resin incorporation rate
• Buffer dispersion
• Coating weight gain
• Drying temperature and humidity
• Wrapping tension
• Packaging seal integrity

Potentially protectable innovations include a coating that controls nicotine onset, a gum matrix with a defined release profile, a low-irritation cinnamon flavor system, or a manufacturing method that improves content uniformity. The strongest enforceable claims would likely be narrow and performance-based rather than broad claims to nicotine gum generally.

What licensing and partnership opportunities exist?

Licensing opportunities are more attractive in manufacturing and distribution than in foundational drug technology.

Potential deal structures include:

• Supply agreements for retailer-branded nicotine gum
• Regional licenses for cinnamon-flavored products
• Contract manufacturing with minimum-volume commitments
• Co-development of improved coatings or packaging
• Bundled distribution with smoking-cessation platforms
• Government and employer cessation-program supply contracts

A supplier with validated nicotine-gum manufacturing capability can create value through regulatory documentation, scale, and reliable quality. A brand owner can contribute retail placement, consumer marketing, and channel access.

What is the revenue exposure and market outlook?

Revenue exposure is linked to category scale, not patent duration. The major commercial variables are:

• Retail price relative to private-label products
• Number of pieces per package
• Repeat purchase rate
• Pharmacy and mass-retail distribution
• Reimbursement or program procurement
• Competition from nicotine pouches
• Smoking prevalence and cessation demand
• Consumer preference for discreet versus behavioral products

The 4 mg strength is strategically important because it addresses higher nicotine dependence and can function as the initial step in a tapering program. A cinnamon product can occupy a differentiated sensory niche, but the flavor must support repeat use rather than only initial trial.

What regulatory status and post-market controls apply?

FDA OTC nicotine gum products must comply with applicable monograph conditions, labeling requirements, current good manufacturing practice requirements, and adverse-event reporting obligations.[1] Manufacturing controls should cover nicotine assay, content uniformity, dissolution or release performance, microbial quality, residual solvents where relevant, flavor stability, and package integrity.

Post-market risks include:

• Accidental pediatric exposure
• Improper chewing and swallowing
• Nausea and gastrointestinal symptoms
• Oral irritation
• Dental or jaw discomfort
• Packaging failures
• Flavor degradation
• Misleading cessation claims

Child-resistant packaging and clear instructions are commercially important even where they do not create exclusivity.

Key takeaways

• Habitrol 4 mg coated cinnamon gum is an established OTC nicotine replacement product with high generic and private-label entry risk.
• The active ingredient and basic nicotine-gum technology do not provide meaningful remaining exclusivity.
• Excipient strategy centers on gum-base texture, buffering, nicotine release, cinnamon flavor control, coating integrity, and moisture protection.
• The most defensible competitive advantages are manufacturing know-how, trade secrets, packaging, retail access, and consumer adherence.
• Orange Book and Paragraph IV strategies are generally less relevant than OTC monograph compliance and product-quality execution.
• The strongest commercial opportunities are private-label supply, improved cinnamon sensory systems, high-barrier packaging, cessation bundles, and regional contract manufacturing.
• Biosimilar risk is not applicable because nicotine polacrilex is a small-molecule drug product, not a biologic.

FAQs

Can a company launch a private-label equivalent of Habitrol 4 mg cinnamon gum?

Yes. The product category is suitable for private-label development if the manufacturer satisfies FDA OTC requirements, labeling rules, quality controls, and lawful marketing conditions.

Is nicotine polacrilex the same as free nicotine?

No. Nicotine polacrilex is a nicotine-resin complex used to incorporate nicotine into chewing gum. Nicotine is released during chewing and becomes available for buccal absorption.

Does cinnamon flavor create patent protection for nicotine gum?

Not by itself. Cinnamon flavor is generally a formulation and branding feature. Protection would require a valid patent with claims directed to a specific composition, coating, release profile, or manufacturing process.

Can nicotine gum be protected through a new coating patent?

Potentially. A coating patent would need claims that distinguish the product from known nicotine gums through defined materials, layer structure, release behavior, stability, or manufacturing parameters.

Are nicotine pouches a direct substitute for 4 mg nicotine gum?

They are commercial substitutes but not formulation equivalents. Nicotine pouches provide discreet use without chewing, while gum offers active behavioral replacement and user-controlled dosing.

References

1. U.S. Food and Drug Administration. (2024). Nicotine replacement therapy products and smoking cessation labeling. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024). DailyMed: Nicotine polacrilex chewing gum labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M006: Smoking cessation drug products for human use. https://www.accessdata.fda.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs
5. World Health Organization. (2023). WHO report on the global tobacco epidemic. https://www.who.int